ALLHAT, the largest ever antihypertensiv e trial, compared cardiac outcomes in 42,418 high-risk individuals with mild-to-moderate hypertension, including 36% with diabetes, randomised to: 1) the thiazide-type diuretic, chlorthalidone; or 2) the ACE inhibitor, lisinopril; or 3) the calcium channel blocker, amlodipine. No differences between the groups were observed for the primary outcome coronary heart disease (CHD) but chlorthalidone was superior in preventing some cardiovascular disease events. Since diuretics are less expensive, it might be inferred that these drugs should be the preferred first-line antihypertensive therapy. However, the design and conduct of ALLHAT make interpretation of the results difficult. Despite its size, ALLHAT has few practical implications for management of hypertension.
Collins R., MacMahon S.Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull1994 ;50:272-98.
2.
MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet1990;335:765-74.
3.
Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990; 335:827-38.
4.
Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA1997;277:739-45.
5.
Hansson L., Lindholm LH, Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet1999;354:1751-6.
6.
Hansson L., Lindholm LH, Niskanen L. et al. for the Captopril Prevention Project (CAPPP) study group.Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial . Lancet1999;353:611-16.
7.
Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) . Lancet2000;356;366-77.
8.
Hansson L., Hedner T., Lund-Johansen P. et al. for the NORDIL Study Group.Randomised trial of effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet2000;356: 359-65.
9.
Blood Pressure LoweringTreatment Trialists' Collaboration.Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet2000;355:1955-64.
10.
Pahor M., Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with the first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet2000; 352:1949-54.
11.
Staessen JA , Wang JG, Thijs L.Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet2001;358:1305-15.
12.
Hansson L., Zanchetti A., Carruthers SG et al. for the HOT Study Group.Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998;351:1755-62.
13.
Tuomilehto J., Rastenyte D., Birkenhager WH et al. for the Systolic Hypertension in Europe Trial Investigators.Effects of calcium channel blockers in older patients with diabetes and systolic hypertension . N Engl J Med1999;340:677-84.
14.
Cushman WC, Reda DJ, Perry HM et al. Regional and racial difference in response to antihypertensive medication use in a randomised controlled trial of men with hypertension in the United States. Arch Intern Med2000;160:825-31.
15.
Rahman M., Douglas JG, Wright JTPathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am1997;26:125-44.
16.
Saunders E. , Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med1990 ;150: 1707-13.
17.
Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens2002;4:393-405.
18.
Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med1997;157:2413-61.
19.
Deary AJ, Schumann AL, Murfet H., Haydock SF, Foo RS-Y, Brown MJDouble-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens2000 ;20:771-7.
20.
Medical Research Council Working Party.Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; of treatment of hypertension in older adults: principal results. BMJ1992; 304:405-12.
21.
Medical Research CouncilWorking Party.MRC trial of treatment of mild hypertension: principal results. BMJ1985;291:97-104.
22.
The IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens1985;3:379-92.
23.
Wikstrand J. , Warnold I., Olsson G., Tuomilehto J., Elmfeldt D., Berglund G.Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA1988;259:1976-82.
24.
Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens1987;5:561-72.
25.
Dahlöf B., Devereux RB, Kjeldsen SE et al., for the LIFE study group.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet2002;359:995-1003.
26.
Cutler JACalcium channel blockers for hypertension - uncertainty continues . N Engl J Med1998;338:679-81.
27.
Furberg CD, Psaty BM, Meyer JVNifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation1995;92; 1326-31.
